Axon Enterprise, Inc. (NASDAQ:AXON) Insider Jeffrey C. Kunins Sells 1,370 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON) insider Jeffrey C. Kunins sold 1,370 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $639.14, for a total value of $875,621.80. Following the completion of the transaction, the insider now directly owns 125,950 shares in the company, valued at approximately $80,499,683. This represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Axon Enterprise Price Performance

AXON stock opened at $635.76 on Wednesday. The stock’s 50 day moving average price is $548.26 and its 200 day moving average price is $411.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The firm has a market cap of $48.48 billion, a P/E ratio of 164.28, a PEG ratio of 14.19 and a beta of 1.01. Axon Enterprise, Inc. has a 1 year low of $241.72 and a 1 year high of $698.67.

Analyst Ratings Changes

A number of research firms recently commented on AXON. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Northland Securities increased their price objective on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. Needham & Company LLC upped their price objective on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, JMP Securities boosted their price target on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $488.67.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. increased its stake in shares of Axon Enterprise by 987.5% in the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 79 shares during the period. Quent Capital LLC boosted its stake in Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 75 shares during the period. Prestige Wealth Management Group LLC grew its holdings in shares of Axon Enterprise by 115.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 44 shares in the last quarter. Brooklyn Investment Group acquired a new position in Axon Enterprise during the third quarter worth $41,000. Finally, Asset Dedication LLC bought a new stake in Axon Enterprise during the 2nd quarter worth about $47,000. 79.08% of the stock is owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.